Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07650058 · ClinicalTrials.gov registry record · NA
Postprandial Effects of Fresh Mango as a Table Sugar Replacement in High-Sugar Breakfasts.
A NA study, sponsored by Ball State University.
- Recruiting
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT07650058: Recruiting NA study, sponsored by Ball State University.
NCT07650058 is a NA study that is actively recruiting participants, run by Ball State University. The registered enrollment target is 35 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07650058, a NA study, is actively recruiting participants, sponsored by Ball State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
Systemic inflammation and intestinal hyperpermeability (disruption of the gut barrier which allows nutrient molecules and bacteria to enter the bloodstream) are triggered by consumption of high-sugar meals and are linked to future development of cardiovascular disease (CVD). Previous research indicates that fresh mangos have properties that have positive effects on the intestinal barrier and local gut inflammation. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to decreased inflammatory and permeability biomarkers after eating a high-sugar breakfast. The investigators will compare the postprandial (post meal) levels of inflammatory (IL-6) and permeability (LPS, lipid binding protein (LBP), and soluble CD14) biomarkers in blood from participants who have consumed a meal sweetened with either sucrose or fresh mango.
Primary Outcome
The investigators will measure LPS at baseline and 30-, 60-, 120-, and 180- minutes after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.
Interventions
- OTHER High-Glycemic Breakfast Containing Cereal and Table Sugar
- OTHER High-Glycemic Breakfast Containing Cereal and Fresh Mango
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2027-01 |
| Phase | NA |
What NCT07650058 shows while recruiting
NCT07650058 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which High-Glycemic Breakfast Containing Cereal and Table Sugar is the first listed.
NCT07650058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07650058 about?
NCT07650058 is a clinical study titled "Postprandial Effects of Fresh Mango as a Table Sugar Replacement in High-Sugar Breakfasts.". Systemic inflammation and intestinal hyperpermeability (disruption of the gut barrier which allows nutrient molecules and bacteria to enter the bloodstream) are triggered by consumption of high-sugar meals and are linked to future development of cardiovascular disease (CVD). Previous research indica...
What is the current status of trial NCT07650058?
This trial is currently recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2026-02-01. Estimated completion is 2027-01.
What interventions are being tested in trial NCT07650058?
The interventions under investigation include: High-Glycemic Breakfast Containing Cereal and Table Sugar (OTHER), High-Glycemic Breakfast Containing Cereal and Fresh Mango (OTHER).
Who is sponsoring clinical trial NCT07650058?
This trial is sponsored by Ball State University, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07650058's enrollment target sits among peer trials
35 1564th of 2000 higher than 431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI